EA201492047A1 - Пролипосомальные композиции тестостерона - Google Patents

Пролипосомальные композиции тестостерона

Info

Publication number
EA201492047A1
EA201492047A1 EA201492047A EA201492047A EA201492047A1 EA 201492047 A1 EA201492047 A1 EA 201492047A1 EA 201492047 A EA201492047 A EA 201492047A EA 201492047 A EA201492047 A EA 201492047A EA 201492047 A1 EA201492047 A1 EA 201492047A1
Authority
EA
Eurasian Patent Office
Prior art keywords
testosterone
compositions
proliposomal
proliposomal powder
testosterone compositions
Prior art date
Application number
EA201492047A
Other languages
English (en)
Other versions
EA028809B1 (ru
Inventor
Гуру В. Бетагери
Рамачандран Тхирукоте
Виран Говда Кададджи
Original Assignee
Вестерн Юниверсити Оф Хелт Сайенсиз
ТЕЗОРКС ФАРМА, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вестерн Юниверсити Оф Хелт Сайенсиз, ТЕЗОРКС ФАРМА, ЭлЭлСи filed Critical Вестерн Юниверсити Оф Хелт Сайенсиз
Publication of EA201492047A1 publication Critical patent/EA201492047A1/ru
Publication of EA028809B1 publication Critical patent/EA028809B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

Изобретение предлагает новые композиции тестостерона, где тестостерон включен в фосфолипид/холестериновую систему с получением пролипосомальной порошкообразной дисперсии. Пролипосомальные порошкообразные дисперсии настоящего изобретения можно объединять с фармацевтически приемлемыми вспомогательными веществами с получением фармацевтических композиций. Изобретение также предлагает пероральные дозированные формы с кишечно-растворимым покрытием для применения в заместительной терапии тестостероном.
EA201492047A 2012-05-09 2013-05-09 Пролипосомальные композиции для доставки тестостерона EA028809B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644996P 2012-05-09 2012-05-09
PCT/US2013/040325 WO2013170012A2 (en) 2012-05-09 2013-05-09 Proliposomal testosterone formulations

Publications (2)

Publication Number Publication Date
EA201492047A1 true EA201492047A1 (ru) 2015-05-29
EA028809B1 EA028809B1 (ru) 2018-01-31

Family

ID=49551459

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201492047A EA028809B1 (ru) 2012-05-09 2013-05-09 Пролипосомальные композиции для доставки тестостерона
EA201791738A EA201791738A1 (ru) 2012-05-09 2013-05-09 Пролипосомальные композиции тестостерона

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791738A EA201791738A1 (ru) 2012-05-09 2013-05-09 Пролипосомальные композиции тестостерона

Country Status (32)

Country Link
US (5) US8957053B2 (ru)
EP (1) EP2846781B1 (ru)
JP (3) JP6055088B2 (ru)
KR (1) KR20150032939A (ru)
CN (2) CN108096192A (ru)
AP (1) AP2014008099A0 (ru)
AR (1) AR091006A1 (ru)
AU (2) AU2013259509B2 (ru)
BR (1) BR112014027942A2 (ru)
CA (1) CA2872779A1 (ru)
CL (1) CL2014003034A1 (ru)
CO (1) CO7240373A2 (ru)
CR (1) CR20140561A (ru)
DO (1) DOP2015000026A (ru)
EA (2) EA028809B1 (ru)
EC (1) ECSP14030572A (ru)
GE (1) GEP201706754B (ru)
HK (3) HK1210409A1 (ru)
IL (1) IL235464B (ru)
IN (1) IN2014DN10383A (ru)
MA (1) MA37610B1 (ru)
MX (1) MX367123B (ru)
MY (1) MY175305A (ru)
NZ (2) NZ721900A (ru)
PE (1) PE20150203A1 (ru)
PH (1) PH12014502498A1 (ru)
SG (2) SG11201407349UA (ru)
TN (1) TN2014000467A1 (ru)
TW (2) TWI664982B (ru)
UA (1) UA115058C2 (ru)
WO (1) WO2013170012A2 (ru)
ZA (2) ZA201408996B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213440B2 (en) 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
KR101682821B1 (ko) 2015-07-21 2016-12-06 서울대학교산학협력단 프로리포솜 제조방법
DK3400072T3 (da) * 2016-01-07 2021-03-22 Tesorx Pharma Llc Formuleringer til behandling af blærecancer
CN108601736A (zh) * 2016-01-08 2018-09-28 健康科学西部大学 前体脂质体十一酸睾酮制剂
KR102574139B1 (ko) 2016-07-07 2023-09-05 삼성전자주식회사 무선 충전 모드를 변경하는 장치 및 방법
US20190343763A1 (en) * 2016-11-11 2019-11-14 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
WO2019096833A1 (en) 2017-11-17 2019-05-23 Evonik Röhm Gmbh Process for preparing a coated hard shell capsule
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
US20200101085A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
KR20220008817A (ko) * 2019-05-15 2022-01-21 에보닉 오퍼레이션스 게엠베하 캡슐 충전 기계를 사용한 (메트)아크릴레이트 공중합체를 기반으로 하는 코팅을 갖는 충전된 경질 쉘 캡슐의 제조 방법
US20220265679A1 (en) * 2019-08-09 2022-08-25 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110747271B (zh) * 2019-12-02 2023-07-18 延边大学 关于pci术后血管损伤-再狭窄程度的标记物
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN112121003B (zh) * 2020-09-29 2022-02-01 江苏集萃新型药物制剂技术研究所有限公司 缓释制剂载药材料及其组合物、缓释制剂及其制备方法
EP4340838A1 (en) * 2021-05-19 2024-03-27 Alberto Paz Orally administered compositions for cancer treatment
CN114668719B (zh) * 2022-02-21 2023-06-16 广东食品药品职业学院 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法
WO2024056062A1 (zh) * 2022-09-16 2024-03-21 长春金赛药业有限责任公司 一种甾体类激素磷脂组合物及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
CA1337397C (en) 1988-09-29 1995-10-24 Hideo Nakajima Emulsified composition
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002051426A2 (en) 2000-12-22 2002-07-04 A Glenn Braswell COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CA2525468A1 (en) 2003-05-12 2004-11-25 Novosom Ag Injectable depots consisting of liposomal aggregates for the delivery of active substances
ES2366646T3 (es) 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
WO2006012502A2 (en) 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
JP2009518443A (ja) 2005-12-06 2009-05-07 リゲル ファーマシューティカルズ インコーポレーティッド 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
US20070154403A1 (en) 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
NZ572308A (en) 2006-03-30 2011-09-30 Univ New York State Res Found Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2146692A1 (en) * 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AU2011320159B2 (en) * 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2845118A1 (en) 2011-08-18 2013-02-21 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same

Also Published As

Publication number Publication date
WO2013170012A2 (en) 2013-11-14
JP2017061552A (ja) 2017-03-30
WO2013170012A3 (en) 2015-06-04
AP2014008099A0 (en) 2014-12-31
EP2846781A4 (en) 2016-03-30
CL2014003034A1 (es) 2015-07-03
EP2846781A2 (en) 2015-03-18
MA37610B1 (fr) 2017-07-31
TN2014000467A1 (en) 2016-03-30
US20150157572A1 (en) 2015-06-11
US9623033B2 (en) 2017-04-18
US20140112986A1 (en) 2014-04-24
MY175305A (en) 2020-06-18
EP2846781B1 (en) 2019-10-30
AU2017272249A1 (en) 2017-12-21
SG11201407349UA (en) 2014-12-30
CR20140561A (es) 2015-02-12
HK1211499A1 (en) 2016-05-27
US8957053B2 (en) 2015-02-17
CA2872779A1 (en) 2013-11-14
AU2013259509A1 (en) 2015-01-15
DOP2015000026A (es) 2015-06-15
JP6208842B2 (ja) 2017-10-04
HK1210409A1 (en) 2016-04-22
GEP201706754B (en) 2017-10-25
JP2015520751A (ja) 2015-07-23
KR20150032939A (ko) 2015-03-31
PE20150203A1 (es) 2015-02-01
PH12014502498A1 (en) 2014-12-22
UA115058C2 (uk) 2017-09-11
US20170065614A1 (en) 2017-03-09
JP2018021062A (ja) 2018-02-08
MA37610A1 (fr) 2016-07-29
CN104780914B (zh) 2018-02-09
TWI614035B (zh) 2018-02-11
ZA201408996B (en) 2017-08-30
TWI664982B (zh) 2019-07-11
JP6368020B2 (ja) 2018-08-01
CN108096192A (zh) 2018-06-01
TW201831169A (zh) 2018-09-01
NZ702634A (en) 2016-09-30
EA028809B1 (ru) 2018-01-31
MX367123B (es) 2019-08-06
AU2013259509B2 (en) 2017-09-07
JP6055088B2 (ja) 2016-12-27
IN2014DN10383A (ru) 2015-08-14
CN104780914A (zh) 2015-07-15
IL235464A0 (en) 2014-12-31
IL235464B (en) 2019-09-26
NZ721900A (en) 2018-01-26
AR091006A1 (es) 2014-12-30
BR112014027942A2 (pt) 2017-06-27
TW201350140A (zh) 2013-12-16
MX2014013450A (es) 2015-05-11
AU2017272249B2 (en) 2019-01-31
ZA201509340B (en) 2018-05-30
SG10201702240TA (en) 2017-05-30
US20160375036A1 (en) 2016-12-29
US9844557B2 (en) 2017-12-19
US20180303850A1 (en) 2018-10-25
US9445995B2 (en) 2016-09-20
HK1255929A1 (zh) 2019-09-06
EA201791738A1 (ru) 2018-03-30
ECSP14030572A (es) 2015-11-30
CO7240373A2 (es) 2015-04-17

Similar Documents

Publication Publication Date Title
EA201791738A1 (ru) Пролипосомальные композиции тестостерона
PH12015501404B1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2014MN02598A (ru)
IN2014DN10548A (ru)
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
BR112015004499A2 (pt) métodos de administração de terapia de pirfenidona
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX349004B (es) Nuevos compuestos.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
JO3810B1 (ar) صيغ التستوستيرون الشحمية المساندة
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU